Background: The implementation of clinical guidelines in care pathways is being promoted for quality assurance in psychiatry and psychotherapy, as in other medical fields. The achievable benefits are disputed and are generally thought to be small. There have been hardly any studies of the effect of clinical care pathways on the costly inpatient treatment of schizophrenic psychoses.
Methods: We conducted a prospective, controlled, before and after study in 114 patients with schizophrenia to determine whether the implementation of a pathway would improve diagnosis and treatment in conformity with published guidelines, and whether there would be any associated improvement in outcome. The patients’ course was extensively documented with a number of structural, process-related, and outcome-related variables in the years before and after pathway implementation. Moreover, two different intensive methods of pathway implementation were tested. Data were collected from 2003 to 2005. The primary indicators of outcome quality included pharmacotherapy-related variables and assessments of treatment efficacy by the physicians, the nurses, and the patients themselves.
Results: After pathway implementation, some diagnostic tests that had been performed only rarely beforehand were performed much more often. The percentage of over- or undermedicated patients, as defined by the treatment pathway, declined markedly. Surprisingly, however, the patients’ multidimensionally documented psychopathological course and their subjective judgments of their condition were worse after pathway implementation than before on all four scales that were used to assess these variables.
Man Who Mistook His Job For His Life / Naomi Shragai
Conclusion: The implementation of a treatment pathway brought about a robust change in process-related variables. The findings of this study furnish no explanation for the observed decline in treatment efficacy.
Meticulous attention to guidelines and their local implementation with the aid of clinical treatment pathways are now being promoted by medical specialty associations, governmental authorities, and health-insurance carriers for the purpose of quality assurance (1). Psychiatric guidelines are now available that meet high standards of quality for both method and content, including those of the German Association for Psychiatry and Psychotherapy (Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde, DGPPN) or the National Institute for Health and Clinical Excellence. It is assumed that such guidelines would effectively assure quality if properly applied in routine clinical practice and be used as the primary decision-making aids that they were designed to be (2, 3). As the creation of guidelines uses up considerable resources (4), they must generate a real benefit to patient care in order to be worthwhile.
Nonetheless, the relevant studies that have been carried out to date have not demonstrated any lasting improvement in the quality of care (5). Guidelines have been found to have no more than a weak influence on physicians’ behavior or on the outcome of treatment (6); whatever effect they have is generally transitory and highly dependent on local implementation strategies (7). Thus, one-time measures such as the imparting of information by didactic lectures, the distribution of printed texts, or the use of checklists are largely ineffective, while combined measures for permanent, continuous support—e.g., regular feedback, a local quality circle, or counseling by trained personnel – seem to be more successful. This general rule also holds, in particular, for the inpatient treatment of patients with schizophrenic psychoses, which is very costly (8), highly variable in quality (9), and thus clearly in need of improvement. Only two methodologically adequate studies on this topic have been published to date (10, 11). Vague assertions are still often made in print to the effect that guideline conformity improves various aspects of treatment outcome (9, 10, 12, 13), but the matter is not at all clear and needs to be examined more closely.
Schiebevorhang Set 5er Mariella Grau/weiss Online Kaufen
We accordingly decided to study whether the implementation of a treatment pathway for schizophrenia actually improves the process variables of management (diagnostics and treatment) as recommended by published guidelines, and also whether this had any effect on the multiple variables by which outcome is measured (psychopathology, subjective condition, medications on discharge). We performed a before and after comparison and tested the effects of two different implementation strategies.
In a prospective before and after study, we documented the course of treatment of 114 schizophrenic patients in detail, in terms of variables relating to management structures, processes, and outcomes, for one year before and one year after the introduction of a clinical treatment pathway. These data were collected in two similar, open, general psychiatric wards, where the treatment pathway was implemented in two different ways:
An overview of the two-year process of data collection and of the patients included in the study is found in Figure 1.
Tory Burch Grey Heron Robinson Small Tote
The study was carried out with prior approval of the responsible institutional ethics committee (Charité Universitätsmedizin Berlin, Campus Benjamin Franklin). The data were collected from 2003 to 2005 at a hospital psychiatric service serving the Steglitz-Zehlendorf district of Berlin. In this naturalistic study, random allocation of patients to the two wards of the service was not feasible. Patients were allotted to whichever ward had a free bed on the day they were admitted.
The treatment pathway was created during the first year of the study by an interdisciplinary working group, none of whose members participated in data collection for the study. The schizophrenia treatment guidelines of the DGPPN, the ICD-10 classification of mental disorders, and the evidence-based pharmacotherapy recommendations of the PORT (Schizophrenia Patient Outcomes Research Team [14, 15]) were used as the basis for the treatment pathway. Its specifications for ancillary diagnostic testing, psychotherapeutic modalities, other specialized treatments, and psychosocial counseling were developed and approved by the staff of the psychiatric service. The pathway’s components were not all compulsory to the same extent: they ranged from general outlines of optional offerings, such as exercise therapy, to binding rules for diagnostic assessment and drug treatment. The pathway was made available in computerized form as a flowchart graphic whose elements could be clicked on to show the relevant text document for each (Figure 2), and the individual documents were connected to each other with links.
On each of the two wards, all patients being treated for a main diagnosis of schizophrenic psychosis (ICD-10 code F20.x) were candidates for inclusion in the study. It was an obligate criterion for inclusion that the manifestations of schizophrenic psychosis had to be the most prominent component of the patient’s clinical condition up to the time of discharge. The criteria for exclusion included inadequate German-language skills for responding to questionnaires and short hospitalizations (for seven days or less), which could generally not be assumed to be routine treatments for acute schizophrenic exacerbations. Data were collected on a maximum of one admission per patient; patients admitted to the service multiple times during the study period were only included in the study the first time.
Intermediate Mechanical Engineer Job With Conrad Consulting
Structural variables—the patients’ sociodemographic data, past medical history, and psychopathology on admission—were documented on established rating scales by the treating physicians (Brief Psychiatric Rating Scale [BPRS]) (16) and nurses (Nurses’ Observation Scale for Inpatient Evaluation [NOSIE]) (17). Rater-training sessions for the physicians and nurses were held every six months over the course of the study. The patients assessed their own conditions with the German-language Frankfurt self-assessment scale for persons with schizophrenia (Frankfurter Befindlichkeits-Skala für schizophren Erkrankte, FBS) (18).
The following process-related variables were recorded at prescribed times, predetermined in relation to the course of the individual patient’s pharmacotherapy (e.g., change of antipsychotic drug for treatment resistance at five weeks, or change to clozapine for treatment resistance at nine weeks):
The outcome variables concerned both pharmacotherapy and the patients’ psychopathology and subjective condition on discharge. An overview of all data collected on the various data collection days over the course of treatment is given in Figure 3.
Ollech & Wajs Valjoux 72 Stainless Steel 1960s
As a further indicator of outcome quality beyond these drug-related treatment variables, the percent improvement of BPRS, NOSIE, and FBS scores in comparison to their admission values was recorded.
As the variables were of diverse types, the statistical tests used to assess them were mostly not distribution-based; the particular tests used in each instance are mentioned in parentheses in the Results section, below. All variables were tested for differences between the period before and the period after introduction of the pathway (“pre” vs. “post”), as well as for differences between the two implementation strategies (“active” vs. “passive”). The p-values given here are meant to serve only as exploratory aids to interpretation; no α-error correction was performed. The statistical analysis was carried out and documented with the aid of SPSS 14.0.
114 patients were included in the study. Their sociodemographic characteristics and aspects of their past medical history are shown in Table 1.
Dainik Asam: E Paper 10 Jan 2022
For clinical reasons, randomization was not possible. We tested for potential differences, both cross-sectional (Ward A vs. Ward B) and longitudinal (“pre” vs. “post”), between patient groups. The groups did not differ significantly with respect to any of the following variables: present age, age at onset of schizophrenia (unifactorial univariate analysis), sex, highest educational level attained, completion or non-completion of vocational training, living situation, marital/familial status, and the distribution of first-episode diseases (chi square test) and the duration of schizophrenia (Kruskal-Wallis-H).
The summated scores on the BPRS (Kruskal-Wallis-H), NOSIE, and FBS (unifactorial univariate variance analysis) on admission were compared across the four patient groups as an indicator of
0 komentar
Posting Komentar